These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28769027)

  • 21. Synergistic killing effect of paclitaxel and honokiol in non-small cell lung cancer cells through paraptosis induction.
    Li XQ; Ren J; Wang Y; Su JY; Zhu YM; Chen CG; Long WG; Jiang Q; Li J
    Cell Oncol (Dordr); 2021 Feb; 44(1):135-150. PubMed ID: 32936421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maackia amurensis agglutinin enhances paclitaxel induced cytotoxicity in cultured non-small cell lung cancer cells.
    Chhetra Lalli R; Kaur K; Dadsena S; Chakraborti A; Srinivasan R; Ghosh S
    Biochimie; 2015 Aug; 115():93-107. PubMed ID: 25978938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hsa_circ_0092887 targeting miR-490-5p/UBE2T promotes paclitaxel resistance in non-small cell lung cancer.
    Wang L; Zhang Z; Tian H
    J Clin Lab Anal; 2023 Jan; 37(1):e24781. PubMed ID: 36550019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
    Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells.
    Zhou X; Sun T; Meng Y; Luo J; Chen J; Xia B; Zhang Z; Cheng Z; Wang X
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of Anti-Metastatic Potential of the Combination of Fisetin with Paclitaxel on A549 Non-Small Cell Lung Cancer Cells.
    Klimaszewska-Wiśniewska A; Hałas-Wiśniewska M; Grzanka A; Grzanka D
    Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic antitumor effect of α-pinene and β-pinene with paclitaxel against non-small-cell lung carcinoma (NSCLC).
    Zhang Z; Guo S; Liu X; Gao X
    Drug Res (Stuttg); 2015 Apr; 65(4):214-8. PubMed ID: 25188609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bazedoxifene Inhibits Cell Viability, Colony-Forming Activity, and Cell Migration in Human Non-Small Cell Lung Cancer Cells and Improves the Treatment Efficacy of Paclitaxel and Gemcitabine.
    Huang Y; Lin J; Fu X; Li L; Fu S
    Clin Respir J; 2024 Aug; 18(8):e13822. PubMed ID: 39152779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted inhibition of the HNF1A/SHH axis by triptolide overcomes paclitaxel resistance in non-small cell lung cancer.
    Li LB; Yang LX; Liu L; Liu FR; Li AH; Zhu YL; Wen H; Xue X; Tian ZX; Sun H; Li PC; Zhao XG
    Acta Pharmacol Sin; 2024 May; 45(5):1060-1076. PubMed ID: 38228910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective effect of caffeic acid on paclitaxel induced anti-proliferation and apoptosis of lung cancer cells involves NF-κB pathway.
    Lin CL; Chen RF; Chen JY; Chu YC; Wang HM; Chou HL; Chang WC; Fong Y; Chang WT; Wu CY; Chiu CC
    Int J Mol Sci; 2012; 13(5):6236-6245. PubMed ID: 22754361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
    Cheng H; An SJ; Dong S; Zhang YF; Zhang XC; Chen ZH; Jian-Su ; Wu YL
    J Hematol Oncol; 2011 Jan; 4():5. PubMed ID: 21255411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polyoxometalate SbW9 regulates proliferation and apoptosis of NSCLC cells via PTEN-dependent AKT signaling pathway.
    Sun HB; Xu L; Wang ZX; Zheng Y; Zhao Y; Yin YY; Han XL; Xu ZN
    Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7959-7967. PubMed ID: 31599421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells.
    Owonikoko TK; Ramalingam SS; Kanterewicz B; Balius TE; Belani CP; Hershberger PA
    Int J Cancer; 2010 Feb; 126(3):743-55. PubMed ID: 19621389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.
    So KS; Rho JK; Choi YJ; Kim SY; Choi CM; Chun YJ; Lee JC
    Anticancer Res; 2015 Mar; 35(3):1537-42. PubMed ID: 25750308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
    Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
    Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individual dose and scheduling determine the efficacy of combining cytotoxic anticancer agents with a kinase inhibitor in non-small-cell lung cancer.
    Meiler J; Guyot M; Hoffarth S; Wesarg E; Höhn Y; Breitenbuecher F; Schuler M
    J Cancer Res Clin Oncol; 2012 Aug; 138(8):1385-94. PubMed ID: 22488173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC.
    Hu Y; Hong Y; Xu Y; Liu P; Guo DH; Chen Y
    Apoptosis; 2014 Nov; 19(11):1627-36. PubMed ID: 25213670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
    Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.